KeViRx is an early-stage pharmaceutical company built on intellectual property licensed from the University of Virginia and the University of Pittsburgh. Its lead compound, KVX-053, is a first-in-class small-molecule inhibitor of the PTP4A3 phosphatase with immunomodulatory and anti-inflammatory properties, aimed at repairing damaged endothelial barriers in acute lung injury. [1]
The company was founded by Elizabeth Sharlow, who is CEO, John Lazo, and Peter Wipf. It initially focused on oncology and has been supported by NIH SBIR grants and other non-dilutive funding, including a $1.99 million U.S. Department of Defense grant awarded in 2024 to advance KVX-053 toward an IND. [2] [3]